Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317’s ability to activate CD40 in a ...
Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...
AZoLifeSciences on MSN
Engineered CD4 CAR T cells reduce amyloid plaques in Alzheimer’s
Findings suggest engineered CD4+ T cells can modify Alzheimer's pathology and improve CNS immune responses, highlighting a ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results